Search Videos and More
News
Dana-Farber Research Publication 5.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors
Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports.
Document
Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) held multidisciplinary meetings on October 15 and November 5, 2021, to discuss recommendations for the use of abemaciclib in patients with early-stage, high-risk, HR+ breast cancer.
Document
Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer
Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) held multidisciplinary meetings on August 4, September 3, and October 8, 2021 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
Symposium
Breast Cancer Treatment Guidelines
Following the FDA approval of certain treatments for breast cancer, the faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center met to formalize guidelines for how to best utilize the new medications.
News
Dana-Farber Research Publications
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2022 Society of Gynecologic Oncology (SGO)
DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.
News
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Dana-Farber Cancer Institute launched a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable anniversary, Dana-Farber seeks to recognize the Institute’s many scientific discoveries, advancements in cancer care for patients, and its extraordinary contributions to eradicating cancer in both children and adults.
News
Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management
This course will address the rapidly changing landscape in the management and treatment of non-Hodgkin lymphoma, Hodgkin Lymphoma, and chronic lymphocytic leukemia
News
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were presented by Dana-Farber's Ursula Matulonis, MD during a plenary session at the SGO 2022 Annual Meeting.
News
Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer
A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial were shared by Panos Konstantinopolous, MD, PhD during a plenary session at the SGO 2022 Annual Meeting.
Symposium
ASCO GU Symposium Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU Symposium